



AMENDMENTS TO THE CLAIMS:

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. **(Presently amended)** A compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

~~A is N, or CH;~~

B is -C₁₋₆alkyl-, -C₀₋₃alkyl-O-C₀₋₃alkyl-, -C₀₋₃alkyl-NH-C₀₋₃alkyl-, -C₀₋₃alkyl-S-C₀₋₃alkyl-, -C₀₋₃alkyl-PH-C₀₋₃alkyl-, -C₀₋₃alkyl-C(O)-C₀₋₃alkyl-, or a direct bond;

X is -C₁₋₆alkyl-, -C₀₋₃alkyl-O-C₀₋₃alkyl-, -C₀₋₃alkyl-NH-C₀₋₃alkyl-, -C₀₋₃alkyl-S-C₀₋₃alkyl-, -C₀₋₃alkyl-PH-C₀₋₃alkyl-, -C₀₋₃alkyl-C(O)-C₀₋₃alkyl-, or a direct bond;

~~D is C or N;~~

~~E is N, O, NH, CH₂, or CH;~~

R, R⁷¹, and R⁷² each independently is hydrogen, OH, -C₀₋₄alkyl-O-C₀₋₄alkyl-, -C₀₋₄alkyl-C(O)-C₀₋₄alkyl-, -C₀₋₄alkyl-C(O)-O-C₀₋₄alkyl-, or C₁₋₄alkyl, any alkyl optionally substituted with 1-6 groups, each group independently being -OH, -NH₂, -NH-CH₃, -N(CH₃)₂, or halogen;

n is 1, 2, 3, or 4;

m is 0, 1, 2, 3, or 4;

n+m is 2, 3, 4, 5, or 6; optionally, one of n CH₂ and one of m CH₂ are bridged by a -C₀₋₂alkyl- linkage;

E¹ is CH, N, or CR⁶;

E² is CH₂, CHR, NH, NR, O, S, -S(O)-, or -S(O)₂-;

R¹ is halogen or C₁₋₄alkyl;

R², R³, R⁴, and R⁶ are each independently halogen, C₁₋₄alkyl, or hydrogen;

and

R⁵ is H, CH₃, or CH₂CH₃.

2. (Canceled)

3. (Canceled)

4. (Presently amended) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

~~A is N;~~

~~D is C;~~

E is NH; and

X is -C₀₋₃alkyl-S-C₀₋₃alkyl-.

5. **(Presently amended)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is N;

D is C;

E is NH;

X is -C₀₋₃alkyl-S-C₀₋₃alkyl-; and

B is a direct bond.

6. **(Original)** The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

E¹ is N; and

E² is NR.

7. **(Original)** The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

E¹ is N;

E² is NR; and

one of n CH₂ and one of m CH₂ are bridged by a -C₀₋₂alkyl- linkage.

8. **(Original)** The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

E¹ is N; and

E² is O.

9. **(Original)** The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

E¹ is N; and

E² is CHR.

10. **(Presently amended)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is N;

D is C;

E is NH;

X is -C₀₋₃alkyl-S-C₀₋₃alkyl-; and

B is NH.

11. **(Original)** The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein

E¹ is CH; and

E² is NR.

12. **(Presently amended)** The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is N;

D is C;


E is NH;


X is -C₀₋₃alkyl-S-C₀₋₃alkyl-; and

B is -C₀₋₃alkyl-O-C₀₋₃alkyl-

13. **(Presently amended)** The compound according to claim 1, represented

by





or a pharmaceutically acceptable salt thereof.

14. **(Original)** A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

15. to 18. **(Canceled)**